渤健公司 BIIB 深 沪
等待开盘 12-02 09:30:00 美东时间
177.78
-4.310
-2.37%
华盛通- 最 高181.78
- 今 开180.15
- 成交量 194.70万股
- 最 低 175.88
- 昨 收 182.09
- 总市值 261.34亿
- 52周最高 185.17
- 市盈率 静 15.89
- 换手率 1.32%
- 52周最低 110.035
- 委 比 -43.77%
- 总股本 1.47亿
- 历史最高 468.55
- 量 比 0.90
- 振 幅 3.24%
- 历史最低 61.605
- 每 手 1
- 风险率 13.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
Eisai Co., Ltd. and Biogen Inc. have filed a new drug application in Japan for LEQEMBI (lecanemab), seeking approval for a subcutaneous autoinjector (SC-AI) as an alternative to intravenous administration. Based on Phase 3 Clarity AD trial data, weekly SC-AI administration at home is safe and effective, with similar clinical benefits to every-other-week IV treatment. If approved, this would be the first anti-amyloid treatment in Japan allowing ho...
11-28 00:30
勇闯“死亡谷”的中国药企越来越多，能否破局？
每经记者 林姿辰 每经编辑 魏官红 被称为医药研发“死亡谷”的阿尔茨海默病（AD），有何魔力？ 11月24日晚间，丹麦制药巨头诺和诺德宣布，针对司美格鲁...
11-27 02:10
CG Oncology Announces New Board Member and Board Transition
CG Oncologyappointed Christina Rossi to its Board of Directors, while Simone Song resigned. Rossi, with over 25 years in pharmaceuticals, brings expertise in launching new therapies. The company is developing cretostimogene, an investigational oncolytic immunotherapy for bladder cancer, with ongoing Phase 3 trials.
11-26 12:00
How Do Investors Really Feel About Biogen Inc?
Biogen Inc's (NYSE:BIIB) short interest as a percent of float has risen 8.75% s...
11-25 04:00
诺和诺德跌近10% 阿尔茨海默病药物临床试验失败
诺和诺德公司（Novo Nordisk，股票代码 NVO）于周一宣布，其一款较早期口服版司美格鲁肽药物用于阿尔茨海默病的临床试验未能实现延缓这种脑衰退疾病进展的...
11-24 23:49
诺和诺德盘前大跌10.5%，阿尔茨海默病药物试验失败
诺和诺德（Novo Nordisk）于周一宣布，其备受关注的阿尔茨海默病药物试验以失败告终。该试验针对的是司美格鲁肽（semaglutide）的一款旧版口服制剂...
11-24 22:19
美股异动丨诺和诺德竞争对手渤健盘前拉升涨超6%
诺和诺德的竞争对手渤健(BIIB.US)盘前拉升涨超6%。消息面上，诺和诺德公司称Evoke 3期试验未显示阿尔茨海默病进展的统计学显著减少。
11-24 19:34
